Skip to main content

Table 3 Multivariate statistic of gender, age, histology, smoking status, treat line, EGFR mutation and SFRP5 methylation for objective response rate (ORR) and disease control rate (DCR)

From: DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Variable Objective response rate (ORR) Disease control rate (DCR)
Univariate Multivariate Univariate Multivariate
P value P value Hazard ratio (95% CI) P value P value Hazard ratio (95% CI)
Gender (male / female) 0.188 0.881 0.926 (0.337-2.542) 0.001 0.115 2.117 (0.834-5.734)
Age (≤65 / >65) 0.351 0.078 2.295 (0.912-5.772) 0.291 0.791 1.110 (0.515-2.393)
Histology (adenocarcinoma / nonadenocarcinoma) 0.002 0.006 6.680 (1.712-26.057) 0.049 0.244 1.663 (0.707-3.915)
Line Treatment (first line / not-first line) 0.016 0.078 2.184 (0.917-5.200) 0.940 0.491 0.756 (0.341-1.678)
Smoking Status (smoker / nonsmoker) 0.016 0.262 0.526 (0.171-1.617) 0.001 0.188 0.524 (0.200-1.371)
EGFR Mutation (wide type / mutation) <0.0001 <0.0001 7.695 (2.895-20.454) <0.0001 0.002 3.255 (1.540-6.881)
SFRP5 Methylation (methylated / unmethylated) 0.222 0.650 0.734 (0.193-2.788) 0.04 0.106 0.434 (0.158-1.193)